Fwd: Extracorporeal orthotics, prosthetics and robotics
MANUFACTURING,DYCOR #
Description
Collection
Title:
Fwd: Extracorporeal orthotics, prosthetics and robotics
Creator:
MANUFACTURING,DYCOR #
Date:
1/12/2021
Text:
Good afternoon OPR practitioners,
I received three responses to my inquiry. To summarize, AOPA might be a good place to direct PDAC policy questions. I would like to take this opportunity to thank AOPA and especially Joe MaTernan's on-going assistance in all things OPR. The second responder suggests individual companies are heavily favored by these new rules. The third responder suggests there is no clinical or engineering basis for PDAC's exclusionary policy and sighted PDAC's perception of clinical OPR (O&P) has a primary contributor and cause of their mechatronic knee and mechanical shin/ankle/foot and more recently ankle foot control system engineering and clinical necessity exclusivity rules.
Now is an unusually dynamic time for extracorporeal OPR clinical engineering and science. OPR is currently standing at threshold mechanical neurobiology and biomechanical clinical science and engineering. Professional appearance and perception as viewed from any number of professional and personal perspectives are and will continue to be really important From your perspective, are mechatronic and mechanical control systems autonomous or semiautonomous? How intimately connected and interactive are - or might be - mechanical and biological systems? Is control passive or active? Are the systems designed to actively augment deficient or compromised neuropsychological and neuromuscular function or are they designed to allow the user or operator of the OPR device to go along for a free ride? Are PDAC policies essentially underwriting industrial interests or are they facilitating clinical care of individuals requiring extracorporeal orthotics, prosthetics and robotics products and services.
If anyone would like to add to this, please let me know if I may post our response; of course anonymously if preferred.
Michael Wilson LP/CPO
> ---------- Original Message ----------
> From: MANUFACTURING,DYCOR # < <Email Address Redacted> >
> To: <Email Address Redacted> < <Email Address Redacted> >
> Date: 01/08/2021 12:57 PM
> Subject: Extracorporeal orthotics, prosthetics and robotics
>
>
> Good afternoon fellow OPR practitioners,
>
> I hope everyone had a safe and special family holiday.
>
> I am a LP/CPO private industry and clinical practice. It is my understanding that without PDAC approval greater clinical restrictions will soon be placed on various foot/ankle components and component systems.
>
> I would like to obtain a consensus of opinion regarding the apparent engineering and clinical criteria used by PDAC for the assessment and implementation of such a selective and exclusionary terminational policy.
>
> Thank you and I wish this year your best year yet,
>
> Michael Wilson LP/CPO member AAOP
> Dycor Mfg Inc.
>
>
>
>
I received three responses to my inquiry. To summarize, AOPA might be a good place to direct PDAC policy questions. I would like to take this opportunity to thank AOPA and especially Joe MaTernan's on-going assistance in all things OPR. The second responder suggests individual companies are heavily favored by these new rules. The third responder suggests there is no clinical or engineering basis for PDAC's exclusionary policy and sighted PDAC's perception of clinical OPR (O&P) has a primary contributor and cause of their mechatronic knee and mechanical shin/ankle/foot and more recently ankle foot control system engineering and clinical necessity exclusivity rules.
Now is an unusually dynamic time for extracorporeal OPR clinical engineering and science. OPR is currently standing at threshold mechanical neurobiology and biomechanical clinical science and engineering. Professional appearance and perception as viewed from any number of professional and personal perspectives are and will continue to be really important From your perspective, are mechatronic and mechanical control systems autonomous or semiautonomous? How intimately connected and interactive are - or might be - mechanical and biological systems? Is control passive or active? Are the systems designed to actively augment deficient or compromised neuropsychological and neuromuscular function or are they designed to allow the user or operator of the OPR device to go along for a free ride? Are PDAC policies essentially underwriting industrial interests or are they facilitating clinical care of individuals requiring extracorporeal orthotics, prosthetics and robotics products and services.
If anyone would like to add to this, please let me know if I may post our response; of course anonymously if preferred.
Michael Wilson LP/CPO
> ---------- Original Message ----------
> From: MANUFACTURING,DYCOR # < <Email Address Redacted> >
> To: <Email Address Redacted> < <Email Address Redacted> >
> Date: 01/08/2021 12:57 PM
> Subject: Extracorporeal orthotics, prosthetics and robotics
>
>
> Good afternoon fellow OPR practitioners,
>
> I hope everyone had a safe and special family holiday.
>
> I am a LP/CPO private industry and clinical practice. It is my understanding that without PDAC approval greater clinical restrictions will soon be placed on various foot/ankle components and component systems.
>
> I would like to obtain a consensus of opinion regarding the apparent engineering and clinical criteria used by PDAC for the assessment and implementation of such a selective and exclusionary terminational policy.
>
> Thank you and I wish this year your best year yet,
>
> Michael Wilson LP/CPO member AAOP
> Dycor Mfg Inc.
>
>
>
>
Citation
MANUFACTURING,DYCOR #, “Fwd: Extracorporeal orthotics, prosthetics and robotics,” Digital Resource Foundation for Orthotics and Prosthetics, accessed November 2, 2024, https://library.drfop.org/items/show/255251.
